1184086-20-1Relevant articles and documents
Targeting of Fumarate Hydratase from Mycobacterium tuberculosis Using Allosteric Inhibitors with a Dimeric-Binding Mode
Whitehouse, Andrew J.,Libardo, M. Daben J.,Kasbekar, Monica,Brear, Paul D.,Fischer, Gerhard,Thomas, Craig J.,Barry, Clifton E.,Boshoff, Helena I. M.,Coyne, Anthony G.,Abell, Chris
supporting information, p. 10586 - 10604 (2019/10/16)
With the growing worldwide prevalence of antibiotic-resistant strains of tuberculosis (TB), new targets are urgently required for the development of treatments with novel modes of action. Fumarate hydratase (fumarase), a vulnerable component of the citric acid cycle in Mycobacterium tuberculosis (Mtb), is a metabolic target that could satisfy this unmet demand. A key challenge in the targeting of Mtb fumarase is its similarity to the human homolog, which shares an identical active site. A potential solution to this selectivity problem was previously found in a high-throughput screening hit that binds in a nonconserved allosteric site. In this work, a structure-activity relationship study was carried out with the determination of further structural biology on the lead series, affording derivatives with sub-micromolar inhibition. Further, the screening of this series against Mtb in vitro identified compounds with potent minimum inhibitory concentrations.
SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS
-
Page/Page column 30, (2011/08/03)
The present invention relates to novel sulfone compounds as 5-HT6 receptor ligands of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable